	US 12,246,038 B2
	Compositions for inducing an immune response
Adrian V S Hill, Oxford (GB); and Irina Redchenko, Oxford (GB)
Assigned to Oxford University Innovation Limited, Oxford (GB)
Appl. No. 17/055,056
Filed by OXFORD UNIVERSITY INNOVATION LIMITED, Oxford (GB)
PCT Filed May 16, 2019, PCT No. PCT/EP2019/062694 § 371(c)(1), (2) Date Nov. 12, 2020, PCT Pub. No. WO2019/219851, PCT Pub. Date Nov. 21, 2019.
Claims priority of application No. 1807932 (GB), filed on May 16, 2018.
Prior Publication US 2021/0213060 A1, Jul. 15, 2021
Int. Cl. A61K 35/17 (2015.01); A61K 39/00 (2006.01); C07K 16/28 (2006.01); C12N 15/86 (2006.01)

CPC A61K 35/17 (2013.01) [A61K 39/00118 (2018.08); A61K 39/001193 (2018.08); C07K 16/2818 (2013.01); C12N 15/86 (2013.01); C12N 2710/24143 (2013.01)]

4 Claims

1. A composition for inducing a T cell mediated immune response for the treatment or prevention of prostate cancer comprising a modified Vaccinia virus Ankara (MVA) vector expressing the 5T4 antigen polypeptide under control of a poxvirus F11 promoter, wherein the vector expresses a polypeptide encoded by a polynucleotide having the nucleic acid sequence of SEQ ID NO: 2.